Table 1.
Baseline Characteristics of the Study Population
| Baseline Characteristic | Evolocumab 140 mg SC Biweekly | Evolocumab 420 mg SC Monthly | Overall |
|---|---|---|---|
| n | 471 | 424 | 895 |
| Age, y, median (IQR) | 58.0 (51.0–66.0) | 60 (52.0–67.0) | 59.0 (51.0–66.0) |
| Female, n (%) | 228 (48.4) | 210 (49.5) | 438 (48.9) |
| LDL‐C, mg/dL, mean (SE) | 132.8 (2.3) | 134.5 (2.4) | 133.6 (1.7) |
| Lp(a), mg/dL, median (IQR) | 40.8 (18.0–82.2) | 48.6 (18.4–83.0) | 46.4 (18.4–82.4) |
| HDL‐C, mg/dL, mean (SE) | 53.6 (0.75) | 55.8 (0.80) | 54.6 (0.55) |
| Triglycerides, mg/dL, median (IQR) | 115.5 (86.5–166.0) | 114.0 (85.0–154.3) | 115.0 (86.0–160.0) |
| Non‐HDL‐C, mg/dL, mean (SE) | 159.5 (2.5) | 160.2 (2.6) | 159.8 (1.8) |
| apoB, mg/dL, mean (SE) | 102.9 (1.5) | 102.4 (1.4) | 102.7 (1.0) |
| PCSK9, ng/mL, mean (SE) | 363.7 (5.8) | 350.5 (6.2) | 357.5 (4.3) |
| hs‐CRP, mg/L, mean (SE) | 3.2 (0.3) | 3.6 (0.5) | 3.4 (0.3) |
| Coronary artery disease, n (%) | 114 (24.2) | 113 (26.7) | 227 (25.4) |
| Cerebrovascular or peripheral arterial disease, n (%) | 56 (11.9) | 59 (13.9) | 115 (12.8) |
| Tobacco use, n (%) | 69 (14.6) | 58 (13.7) | 127 (14.2) |
| Diabetes mellitus, n (%) | 58 (12.3) | 45 (10.6) | 103 (11.5) |
| Hypertension, n (%) | 231 (49.0) | 216 (50.9) | 447 (49.9) |
| Family history of premature coronary heart disease, n (%) | 123 (26.1) | 116 (27.4) | 239 (26.7) |
apoB indicates apolipoprotein B; HDL‐C, high‐density lipoprotein cholesterol; hs‐CRP, high‐sensitivity C‐reactive protein; IQR, interquartile range; LDL‐C, low‐density lipoprotein cholesterol; Lp(a), lipoprotein(a); PCSK9, proprotein convertase subtilisin/kexin type 9; SC, subcutaneous.